check web redirect url status code checker

Check server response of

Server response
NS records
Whois domain
Response headers
Request headers
Raw HTML code
301 Moved Permanently - oab3.com
HTTP Status: 301
User-Agent: Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; [email protected])
Date: Fri, 09 May 2025 04:17:12 GMT
Content-Type: text/html; charset=utf-8
Content-Length: 174
Connection: keep-alive
Location: https://www.myrbetriqhcp.com/mechanism-of-action/?utm_source=haymarket_run&utm_medium=print&utm_campaign=2019mp&utm_content=moa
Server: ip-100-74-5-21.eu-west-2.compute.internal
Vary: Accept-Encoding
X-Request-Id: c950406f-4878-4862-8f00-ada038b599d3

HTTP Code 301 Moved Permanently

301 status code means that the requested resource has been permanently moved to a new URL. All future requests should use the new address.

When is Code 301 used?

  • When changing a website domain
  • When modifying URL structures
  • When setting up redirects for SEO

What does Code 301 mean for the user?

The browser will automatically redirect the user to the new address, and search engines will update their indexes.

200 OK - https://www.myrbetriqhcp.com/mechanism-of-action/?utm_source=haymarket_run&utm_medium=print&utm_campaign=2019mp&utm_content=moa
HTTP Status: 200
User-Agent: Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; [email protected])
Content-Length: 41472
Content-Type: text/html; charset=utf-8
Date: Fri, 09 May 2025 04:17:12 GMT
Server: Microsoft-IIS/10.0
Access-Control-Expose-Headers: Request-Context
Cache-Control: private,no-cache,no-Store
Expires: -1
Pragma: no-cache
Set-Cookie: kppid=uivEGzEQFB8; expires=Sat, 10-May-2025 04:17:12 GMT; path=/; secure; HttpOnly
Set-Cookie: ASP.NET_SessionId=tnuf1y1zxswzg4j5wbpqvsv1; path=/; secure; HttpOnly; SameSite=Lax
Set-Cookie: GaGuid=4fc746a0334947328970e0ed0d9dcf95; expires=Sun, 09-Nov-2025 04:17:12 GMT; path=/; secure; HttpOnly
Set-Cookie: ARRAffinity=6cf0ee4aeee40363a7a458dce8238c6b2d321cda622457cdeb007b8171d8984f;Path=/;HttpOnly;Secure;Domain=www.myrbetriqhcp.com
Set-Cookie: ARRAffinitySameSite=6cf0ee4aeee40363a7a458dce8238c6b2d321cda622457cdeb007b8171d8984f;Path=/;HttpOnly;SameSite=None;Secure;Domain=www.myrbetriqhcp.com
X-AspNetMvc-Version: 5.2
X-AspNet-Version: 4.0.30319
X-HTML-Minification-Powered-By: WebMarkupMin
Request-Context: appId=cid-v1:b67357b8-1362-43fc-9d8f-0083f2a71f76
X-Powered-By: ASP.NET
X-Frame-Options: SAMEORIGIN

HTTP Code 200 OK

200 status code is a standard successful HTTP server response. It means that the client’s request (e.g., from a browser) was successfully processed, and the server is delivering the requested data.

When is Code 200 used?

  • When loading a web page
  • When successfully receiving an API response
  • When processing a form or another HTTP request

What does Code 200 mean for the user?

The user receives content without errors, and the page or application functions properly. If Code 200 is accompanied by data, the browser or program processes and displays it to the user.

GET / HTTP/1.1
Host: oab3.com
Accept: */*
User-Agent: Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; [email protected])

<!DOCTYPE html><html lang=en><head><script src=https://cdn.cookielaw.org/consent/018fc50a-40ea-75ab-89af-f342a70f43f9-test/OtAutoBlock.js></script><script src=https://cdn.cookielaw.org/scripttemplates/otSDKStub.js charset=UTF-8 data-domain-script=018fc50a-40ea-75ab-89af-f342a70f43f9-test></script><script>function OptanonWrapper(){}</script><script src=https://cdn.pullthrough.tools/CommercialSite/js/PFV_v2.js></script><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-5NTDS2');</script><script>window.DEFER=window.DEFER?window.DEFER:[];</script><meta charset=utf-8><meta name=viewport content="width=device-width, initial-scale=1.0"><meta name=google-site-verification content=NPMaiSL11lRg2xVFtsNJeT7IXNd27FgAUoIDQe7g-HI><meta name=description content="Read how MYRBETRIQ targets the beta-3 adrenergic receptor pathway and watch a video from Dr. Nathaniel Barnes that explains how MYRBETRIQ works. MYRBETRIQ for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency."><meta name=canonical content="https://www.myrbetriqhcp.com/mechanism-of-action/"><meta http-equiv=Content-Security-Policy content=upgrade-insecure-requests><script>if(screen.width>=768){document.querySelector('meta[name="viewport"]').setAttribute("content","width=1024");}</script><title>Mechanism of Action | MYRBETRIQ&reg; (mirabegron ER tablets)</title><link href=/Content/style/css/style.css rel=stylesheet><link href=/Content/style/css/pillar.css rel=stylesheet><link href=https://vjs.zencdn.net/8.3.0/video-js.css rel=stylesheet><script>window.HELP_IMPROVE_VIDEOJS=false;</script><script src=/Content/js/vendor/modernizr-custom.js></script><!--[if lte IE 8]><script src="/bundles/ie8?v=ea5_1tTNJAmuLANOQ6G-tNYGyaD6WYmmEAGm5MfrsXw1" defer></script><![endif]--><body class=is-moa><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5NTDS2" height=0 width=0 style=display:none;visibility:hidden></iframe></noscript><script type=application/ld+json>
    {"@context":"http://schema.org", "type":"MedicalCondition", "name":"Overactive Bladder", "sameAs":"https://en.wikipedia.org/wiki/Overactive_bladder", "code":"N32.81", "associatedAnatomy":"Bladder", "possibleTreatment":{"@type":"MedicalTherapy", "drug":{"@type": "Drug", "name": "MYRBETRIQ® (mirabegron)", "proprietaryName": "MYRBETRIQ®", "mainEntityOfPage": "https://www.myrbetriqhcp.com/", "warning": ["IMPORTANT SAFETY INFORMATION", "Do not use Myrbetriq in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet. Solifenacin succinate is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product. Myrbetriq alone or in combination with solifenacin succinate can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Myrbetriq is not recommended for use in severe uncontrolled hypertensive patients (defined as systolic blood pressure ≥ 180mm Hg and/or diastolic blood pressure ≥ 110mm Hg). Worsening of hypertension was reported infrequently in Myrbetriq clinical trial patients with OAB. In patients taking Myrbetriq, urinary retention has been reported in patients with bladder outlet obstruction (BOO) and in patients taking antimuscarinic medications for the treatment of OAB. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in Myrbetriq patients; however, Myrbetriq and solifenacin succinate should still be administered with caution to patients with clinically significant BOO. For example, monitor these patients for signs and symptoms of urinary retention. Myrbetriq should also be administered with caution to patients taking antimuscarinic medications for the treatment of OAB, including solifenacin succinate. Angioedema of the face, lips, tongue and/or larynx has been reported with Myrbetriq and with solifenacin succinate. Cases of angioedema have been reported to occur hours after the first dose or after multiple doses. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, promptly discontinue Myrbetriq and/or solifenacin succinate and initiate appropriate therapy and/or measures necessary to ensure a patent airway. Solifenacin succinate should be administered with caution to patients with decreased gastrointestinal motility, controlled narrow-angle glaucoma or reduced renal or hepatic function. Doses of solifenacin succinate higher than 5mg are not recommended in patients with severe renal impairment, moderate hepatic impairment, or when administered with ketoconazole or other potent CYP3A4 inhibitors. Use of solifenacin succinate in patients with severe hepatic impairment is not recommended. Anticholinergic central nervous system (CNS) effects have been reported with solifenacin succinate use, including headache, confusion, hallucinations and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing dose, and be advised not to drive or operate heavy machinery until they know how solifenacin succinate affects them. If a patient experiences these effects, dose reduction or drug discontinuation should be considered. Since Myrbetriq is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6 substrates such as metoprolol and desipramine is increased when co-administered with Myrbetriq. Therefore, appropriate monitoring and dose adjustment may be necessary, especially with narrow therapeutic index drugs metabolized by CYP2D6, such as thioridazine, flecainide, and propafenone. In solifenacin succinate monotherapy studies, for the 5mg dose one serious adverse event (angioneurotic edema) was reported. For the 10mg dose, three intestinal serious adverse events were reported (one fecal impaction, one colonic obstruction and one intestinal obstruction). In clinical trials, the most commonly reported adverse reactions (> 2% and > placebo) for Myrbetriq 25mg and 50mg versus placebo, respectively, were hypertension (11.3%, 7.5% vs. 7.6%), nasopharyngitis (3.5%, 3.9% vs. 2.5%), urinary tract infection (4.2%, 2.9% vs. 1.8%), and headache (2.1%, 3.2% vs. 3.0%). In clinical trials, the most commonly reported adverse reactions (> 2% and > placebo and > comparator) for Myrbetriq in combination with solifenacin succinate 25mg + 5mg and 50mg + 5mg versus Myrbetriq 25mg, Myrbetriq 50mg, solifenacin succinate 5mg and placebo, respectively, were dry mouth (9.3%, 7.2% vs. 3.8%, 3.6%, 6.5%, 2.2%), urinary tract infection (7.0%, 4.0% vs. 4.0%, 4.2%, 3.6%, 5.3%), constipation (4.2%, 3.9% vs. 1.2%, 2.8%, 2.4%, 1.2%), and tachycardia (2.2%, 0.9% vs. 1.6%, 1.6%, 0.7%, 0.8%). In postmarketing experience with mirabegron, the following events have also occurred: atrial fibrillation, nausea, constipation, diarrhea, and dizziness. Please see accompanying complete Prescribing Information for Myrbetriq® (mirabegron)."], "manufacturer":{"name":"Astellas Pharma Inc.", "description":"The Astellas Group’s business philosophy has three elements — raison d'être, mission and beliefs.", "url":"https://www.astellas.com/", "Brand":{"@type": "Brand", "name": "MYRBETRIQ®", "url": "https://www.myrbetriqhcp.com/"}}}, "indication":["Myrbetriq is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency"]}}
</script><header class="l-header js-header"><div class=header-wrapper id=header-wrapper><div class=top-bar><div class=container><div class=m-header-topnav><ul class=topnav-info-links><li class="topnav-item larger-size"><a href=https://www.astellas.com/us/system/files/Myrbetriq_WPI.pdf target=_blank rel=noopener>Full Prescribing Information</a><li class="topnav-item larger-size"><a href="/support/" class="section-link js-isi-link">Important Safety Information</a><li class="topnav-item desktop-only"><a href=https://astellasresources.com/urology-resources target=_blank rel=noopener>Urology Resources</a><li class="topnav-item desktop-only"><a href="https://www.myrbetriq.com/" target=_blank rel=noopener>Patient Site</a></ul><ul class=topnav-social-media></ul></div></div></div><div class="margin-top-20 main-header-container"><div class=main-header-container-nav><a href="/" class=m-header-logo> <img src=/Content/img/myrbetriqlogo.svg alt="MYRBETRIQ (mirabegron) logo" width=235 height=105> </a><div class=m-header-main-nav><nav class=m-header-nav><ul class=main-nav><li class="nav-item is-home mobile-only"><a class=nav-link href="/">Home</a><li class="nav-item is-selected"><a class=nav-link href="/mechanism-of-action/">Mechanism <br class=desktop-only>of Action</a><li class=nav-item><a class=nav-link href="/efficacy/">Efficacy</a> <a class=subnav-expand></a><ul class=subnav><li class=nav-item><a class=nav-link href="/efficacy/">Study Design</a><li class=nav-item><a class="nav-link lesser-padding" href="/efficacy/clinical-studies/">Efficacy Results</a><li class=nav-item><a class="nav-link lesser-padding" href="/efficacy/pillar-study-design/">Adults ≥65 (PILLAR): <br class=footer-only-break>Study Design</a><li class=nav-item><a class="nav-link lesser-padding" href="/efficacy/pillar-results/">Adults ≥65 (PILLAR): <br class=footer-only-break>Efficacy Results</a></ul><li class=nav-item><a class=nav-link href="/safety/">Safety</a> <a class=subnav-expand></a><ul class=subnav><li class=nav-item><a class=nav-link href="/safety/">Safety Results</a><li class=nav-item><a class="nav-link lesser-padding" href="/safety/pillar-results/">Adults ≥65 (PILLAR): <br class=footer-only-break>Safety Results </a></ul><li class=nav-item><a class=nav-link href="/dosing/">Dosing &amp; <br class=desktop-only>Administration</a> <a class=subnav-expand></a><ul class=subnav><li class=nav-item><a class=nav-link href="/dosing/">Dosing</a><li class=nav-item><a class=nav-link href="/dosing/drug-interactions/">Drug-to-Drug Interactions</a></ul><li class="is-combo-treatment nav-item"><a class=nav-link href="/combination-treatment/">Combination <br>Treatment</a> <a class=subnav-expand></a><ul class=subnav><li class=nav-item><a class=nav-link href="/combination-treatment/">MOA</a><li class=nav-item><a class=nav-link href="/combination-treatment/combination-therapy/">Combination Therapy</a><li class=nav-item><a class=nav-link href="/combination-treatment/addon-therapy/">Add-on Therapy</a><li class=nav-item><a class=nav-link href="/combination-treatment/safety/">Safety</a><li class=nav-item><a class=nav-link href="/combination-treatment/dosing/">Dosing</a></ul><li class=nav-item><a class=nav-link href="/elderly-care/">Elderly <br class=desktop-only>Care</a><li class="nav-item access-list"><a class=nav-link href="/downloadable-resources/">Resources</a></ul><ul class=secondary-nav><li class=nav-item><a class="nav-link is-pi" href=https://www.astellas.com/us/system/files/Myrbetriq_WPI.pdf rel=noopener target=_blank>Full Prescribing Information</a><li class=nav-item><a class=nav-link href=/isi>Important Safety Information</a><li class=nav-item><a class=nav-link href="https://astellasresources.com/?utm_source=myrbetriqhcp&amp;utm_medium=referral&amp;utm_term=hcp&amp;utm_content=offsite+link&amp;utm_campaign=16+hcp+site" target=_blank rel=noopener>Urology Resources</a><li class=nav-item><a class=nav-link href="https://www.myrbetriq.com/" target=_blank rel=noopener>Patient Site</a></ul></nav></div><a class=m-btn-mobile-nav></a></div></div></div><div class=page-subnav id=page-subnav-desktop><div class=container><div class=row><div class=col-xs-12><nav class="subnav efficacy"><div class=nav-item><a class=nav-link href="/efficacy/">Study Design</a></div><div class=nav-item><a class=nav-link href="/efficacy/clinical-studies/">Efficacy Results</a></div><div class=nav-item><a class=nav-link href="/efficacy/pillar-study-design/">Adults &ge;65 (PILLAR): Study Design</a></div><div class=nav-item><a class=nav-link href="/efficacy/pillar-results/">Adults &ge;65 (PILLAR): Efficacy Results</a></div></nav> <nav class="subnav safety"><div class=nav-item><a class=nav-link href="/safety/">Safety Results</a></div><div class=nav-item><a class=nav-link href="/safety/pillar-results/">Adults ≥65 (PILLAR): Safety Results</a></div></nav> <nav class="subnav administration"><div class=nav-item><a class=nav-link href="/dosing/">Dosing</a></div><div class=nav-item><a class=nav-link href="/dosing/drug-interactions/">Drug-to-Drug Interactions</a></div></nav> <nav class="subnav treatment"><div class=nav-item><a class=nav-link href="/combination-treatment/">MOA</a></div><div class=nav-item><a class=nav-link href="/combination-treatment/combination-therapy/">Combination Therapy</a></div><div class=nav-item><a class=nav-link href="/combination-treatment/addon-therapy/">Add-on Therapy</a></div><div class=nav-item><a class=nav-link href="/combination-treatment/safety/">Safety</a></div><div class=nav-item><a class=nav-link href="/combination-treatment/dosing/">Dosing</a></div></nav> <nav class="subnav support">  </nav></div></div></div></div></header><section class=m-hero><div class=container><h1 class=m-hero-title>GO with the first <br class=desktop-only> FDA&#8209;approved &beta;<sub>3</sub>&#45;<br class=mobile-only>adrenergic&nbsp;agonist<sup class=superscript-rokkitt>1</sup></h1></div></section><section class="l-pageblock-white no-padding-bottom"><div class=container><h2 class="left-rhythm-padding extra-margin">See how Myrbetriq<sup class="is-rokkitt bold">&reg;</sup> (mirabegron extended-release tablets) targets the &beta;<sub>3</sub>&#8209;AR&nbsp;pathway</h2><p class="left-rhythm-padding right-rhythm-padding larger">Myrbetriq is not an antimuscarinic agent.<sup>1</sup> It targets a different receptor signaling pathway&mdash;the <span class=is-beta>&#946;</span><sub>3</sub>-adrenergic receptor (AR) pathway.<div class="row left-rhythm-padding"><div class=col-lg-12><div class=desktop-only><script src=https://fast.wistia.com/embed/medias/0fdx95ty24.jsonp async></script><script src=https://fast.wistia.com/assets/external/E-v1.js async></script><div class=wistia_responsive_padding style="padding:67.71% 0 0 0;position:relative"><div class=wistia_responsive_wrapper style=height:100%;left:0;position:absolute;top:0;width:100%><div class="wistia_embed wistia_async_0fdx95ty24 seo=false videoFoam=true" style=height:100%;position:relative;width:100%><div class=wistia_swatch style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%"><img src=https://fast.wistia.com/embed/medias/0fdx95ty24/swatch style=filter:blur(5px);height:100%;object-fit:contain;width:100% alt="" aria-hidden=true onload="this.parentNode.style.opacity=1"></div></div></div></div></div><div class=mobile-only><a data-toggle=modal data-target=#isHomeVideo data-modal-content=home-video> <img src=https://embed-ssl.wistia.com/deliveries/5ca50cfb1feea1c45b9d56ab89b093f8.webp> </a></div><div class=video-description-container><p class=larger>Overactive bladder (OAB) is characterized by involuntary contraction of the detrusor <br class=desktop-only>muscle during the storage phase.<sup>2</sup><ul><li class=myrbetriq-relaxes-list><p class=larger>Myrbetriq relaxes the detrusor smooth muscle during the storage phase of the <br class=desktop-only>urinary bladder fill-void cycle by activation of the &beta;<sub>3</sub>-AR<sup>1</sup><ul><li><p class=larger>As a result, bladder capacity is increased</ul><li><p class=larger>Mirabegron is an agonist of the human &beta;<sub>3</sub>-AR as demonstrated by in vitro <br class=desktop-only>laboratory experiments using the cloned human &beta;<sub>3</sub>-AR<sup>1</sup><li><p class=larger>Although mirabegron showed very low intrinsic activity for cloned human &beta;<sub>1</sub>-AR and <br class=desktop-only> &beta;<sub>2</sub>- AR, results in humans indicate that &beta;<sub>1</sub>-AR stimulation occurred at a dose of 200 mg<sup>1</sup></ul></div></div></div></div></section><section class=moa-according><div class="container moa-therapies"><h2 class=left-rhythm-padding>According to the AUA/SUFU Guideline, behavioral <br class=desktop-only>therapies may be combined with Myrbetriq as a <br class=desktop-only>first-line treatment&nbsp;option<sup>3</sup></h2><div class=left-rhythm-padding><p class="no-margin larger">Other pharmacologic treatment options may also be combined with behavioral therapies <br class=desktop-only>for first-line use. Adapted from AUA/SUFU (American Urological Association/Society of <br class=desktop-only>Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction) non-neurogenic <br class=desktop-only>OAB&nbsp;guidelines.</div></div></section><section class="l-pageblock-grey video-references-section"><div class=container><h2 class=left-rhythm-padding>Dr. Nathaniel Barnes explains how Myrbetriq works</h2><p class="larger left-rhythm-padding">Watch this video about the first FDA&#8209;approved &beta;<sub>3</sub>&#8209;adrenergic agonist. See how Myrbetriq <br class=desktop-only>targets the &beta;<sub>3</sub>&#8209;AR&nbsp;pathway.<div class="left-rhythm-padding video-full"><div class=desktop-only><script src=https://fast.wistia.com/embed/medias/vwwevn6uf4.jsonp async></script><script src=https://fast.wistia.com/assets/external/E-v1.js async></script><div class=wistia_responsive_padding style="padding:67.71% 0 0 0;position:relative"><div class=wistia_responsive_wrapper style=height:100%;left:0;position:absolute;top:0;width:100%><div class="wistia_embed wistia_async_vwwevn6uf4 seo=false videoFoam=true" style=height:100%;position:relative;width:100%><div class=wistia_swatch style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%"><img src=https://fast.wistia.com/embed/medias/vwwevn6uf4/swatch style=filter:blur(5px);height:100%;object-fit:contain;width:100% alt="" aria-hidden=true onload="this.parentNode.style.opacity=1"></div></div></div></div></div><div class=mobile-only><a data-toggle=modal data-target=#isBarnesVideo data-modal-content=barnes-video> <img src=https://embed-ssl.wistia.com/deliveries/d1f6d1d3ebfd704a67c9b82f219d3466.webp> </a></div></div></div></section><div id=psp class=psp><div class=psp-bar><div class=container><p>Important Safety Information, <br class=mobile-only>Indications&nbsp;and&nbsp;Usage<div class=psp-bar-controls><div class=psp-bar-show-more-button><span>Show more</span> <span>Show less</span> <svg viewBox="0 0 129 80"><path fill=none stroke=currentColor stroke-width=23 stroke-miterlimit=10 d="M8.9 71.6l55.9-55.1 55.6 55.1"></path></svg></div></div></div></div><div class=isi><div><div class="container is-isi"><div class="isi-wrapper left-rhythm-padding right-rhythm-padding"><h4 class="small grey hidden-when-closed isi-heading">INDICATIONS AND USAGE</h4><p class=hidden-when-closed>MYRBETRIQ<sup class=reg-sup>®</sup> (mirabegron extended-release tablets), either alone or in combination with the muscarinic antagonist solifenacin succinate, is indicated for the treatment of overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency.<h4 class="small grey hidden-when-closed isi-heading">IMPORTANT SAFETY INFORMATION</h4><aside class=hidden-when-open-inline-mobile><p class=cl-psp-close-position-mobile>MYRBETRIQ is contraindicated in patients with known hypersensitivity reactions to mirabegron or any inactive ingredients of <span class=text-nowrap>the tablet</span>.<p>MYRBETRIQ monotherapy or in combination with solifenacin succinate can increase blood pressure in adults. Periodic blood pressure determinations are recommended, especially in hypertensive patients. MYRBETRIQ is not recommended for use in patients with severe uncontrolled hypertension (defined as systolic blood pressure ≥ <span class=text-nowrap>180mm Hg</span> and/or diastolic blood pressure ≥ <span class=text-nowrap>110mm Hg</span>). Worsening of pre-existing hypertension was reported infrequently in patients taking MYRBETRIQ.</aside><div class=hidden-when-closed-mobile><p>MYRBETRIQ is contraindicated in patients with known hypersensitivity reactions to mirabegron or any inactive ingredients of <span class=text-nowrap>the tablet</span>.<p>MYRBETRIQ monotherapy or in combination with solifenacin succinate can increase blood pressure in adults. Periodic blood pressure determinations are recommended, especially in hypertensive patients. MYRBETRIQ is not <span class=cl-psp-close-position-desktop></span>recommended for use in patients with severe uncontrolled hypertension (defined as systolic blood pressure ≥ <span class=text-nowrap>180mm Hg</span> and/or diastolic blood pressure ≥ <span class=text-nowrap>110mm Hg</span>). Worsening of pre-existing hypertension was reported infrequently in patients taking MYRBETRIQ.<p>In patients taking MYRBETRIQ, urinary retention has been reported in patients with bladder outlet obstruction (BOO) and in patients taking muscarinic antagonist medications for the treatment of OAB. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in patients treated with mirabegron; however, MYRBETRIQ should still be administered with caution to patients with clinically significant BOO. For example, monitor these patients for signs and symptoms of urinary retention. MYRBETRIQ should also be administered with caution to patients taking muscarinic antagonist medications for the treatment of OAB, including solifenacin succinate.<p>Angioedema of the face, lips, tongue and/or larynx has been reported with MYRBETRIQ. In some cases, angioedema occurred after the first dose. Cases have been reported to occur hours after the first dose or after multiple doses. Angioedema, associated with upper airway swelling, may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, promptly discontinue MYRBETRIQ and initiate appropriate therapy and/or measures necessary to ensure a patent airway.<p>Since MYRBETRIQ is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6 substrates is increased when co‐administered with MYRBETRIQ. Therefore, appropriate monitoring and dose adjustment may be necessary, especially with narrow therapeutic index drugs metabolized by CYP2D6.<p>In clinical trials, the most commonly reported adverse reactions in adults (> 2% and > placebo) for MYRBETRIQ 25mg and 50mg versus placebo, respectively, were hypertension (11.3%, 7.5% vs. 7.6%), nasopharyngitis (3.5%, 3.9% vs. 2.5%), urinary tract infection (4.2%, 2.9% vs. 1.8%), and headache (2.1%, 3.2% vs. 3.0%).<p>In clinical trials, the most commonly reported adverse reactions in adults (> 2% and > placebo and > comparator) for MYRBETRIQ in combination with solifenacin succinate 25mg + 5mg and 50mg + 5mg versus MYRBETRIQ 25mg, MYRBETRIQ 50mg, solifenacin succinate 5mg, and placebo, respectively, were dry mouth (9.3%, 7.2% vs. 3.8%, 3.6%, 6.5%, 2.2%), urinary tract infection (7.0%, 4.0% vs. 4.0%, 4.2%, 3.6%, 5.3%), constipation (4.2%, 3.9% vs. 1.2%, 2.8%, 2.4%, 1.2%), and tachycardia (2.2%, 0.9% vs. 1.6%, 1.6%, 0.7%, 0.8%).<p>In postmarketing experience with mirabegron, the following events have also occurred: atrial fibrillation, nausea, diarrhea, <span class=text-nowrap>and dizziness</span>.<p>Please refer to prescribing information for solifenacin succinate when prescribing MYRBETRIQ in combination with solifenacin succinate.<p class=no-margin-bottom><strong><a href=https://www.astellas.com/us/system/files/Myrbetriq_WPI.pdf target=_blank rel=noopener class=is-underlined>Please click here for complete Prescribing Information for Myrbetriq<sup class=reg-sup>®</sup> (mirabegron extended-release tablets)</a></strong></div></div></div></div></div></div><div class=references-wrapper><div class=container><div class="left-rhythm-padding right-rhythm-padding"><h4 class="small grey">References</h4><p class="references no-margin"><strong>1.</strong>&nbsp;Myrbetriq [package insert]. Northbrook, IL: Astellas Pharma US, Inc. <strong>2.</strong>&nbsp;Chu FM, Dmochowski R. Pathophysiology of overactive bladder. Am J Med. 2006;119(3 Suppl 1):3S&#8209;8S. <strong>3.</strong>&nbsp;Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association Education and Research, Inc. 2019.</div></div></div><div class="l-footer footer-nav"><div class=container><div class="footer-links cf desktop-only"><ul class=main-nav><li class="nav-item is-home mobile-only"><a class=nav-link href="/">Home</a><li class="nav-item is-selected"><a class=nav-link href="/mechanism-of-action/">Mechanism <br class=desktop-only>of Action</a><li class=nav-item><a class=nav-link href="/efficacy/">Efficacy</a> <a class=subnav-expand></a><ul class=subnav><li class=nav-item><a class=nav-link href="/efficacy/">Study Design</a><li class=nav-item><a class="nav-link lesser-padding" href="/efficacy/clinical-studies/">Efficacy Results</a><li class=nav-item><a class="nav-link lesser-padding" href="/efficacy/pillar-study-design/">Adults ≥65 (PILLAR): <br class=footer-only-break>Study Design</a><li class=nav-item><a class="nav-link lesser-padding" href="/efficacy/pillar-results/">Adults ≥65 (PILLAR): <br class=footer-only-break>Efficacy Results</a></ul><li class=nav-item><a class=nav-link href="/safety/">Safety</a> <a class=subnav-expand></a><ul class=subnav><li class=nav-item><a class=nav-link href="/safety/">Safety Results</a><li class=nav-item><a class="nav-link lesser-padding" href="/safety/pillar-results/">Adults ≥65 (PILLAR): <br class=footer-only-break>Safety Results </a></ul><li class=nav-item><a class=nav-link href="/dosing/">Dosing &amp; <br class=desktop-only>Administration</a> <a class=subnav-expand></a><ul class=subnav><li class=nav-item><a class=nav-link href="/dosing/">Dosing</a><li class=nav-item><a class=nav-link href="/dosing/drug-interactions/">Drug-to-Drug Interactions</a></ul><li class="is-combo-treatment nav-item"><a class=nav-link href="/combination-treatment/">Combination <br>Treatment</a> <a class=subnav-expand></a><ul class=subnav><li class=nav-item><a class=nav-link href="/combination-treatment/">MOA</a><li class=nav-item><a class=nav-link href="/combination-treatment/combination-therapy/">Combination Therapy</a><li class=nav-item><a class=nav-link href="/combination-treatment/addon-therapy/">Add-on Therapy</a><li class=nav-item><a class=nav-link href="/combination-treatment/safety/">Safety</a><li class=nav-item><a class=nav-link href="/combination-treatment/dosing/">Dosing</a></ul><li class=nav-item><a class=nav-link href="/elderly-care/">Elderly <br class=desktop-only>Care</a><li class="nav-item access-list"><a class=nav-link href="/downloadable-resources/">Resources</a></ul></div><div class="footer-links cf mobile-only"><ul class=main-nav><li class="nav-item is-home mobile-only"><a class=nav-link href="/">Home</a><li class="nav-item nav-list is-selected"><a class=nav-link href="/mechanism-of-action/">Mechanism <br class=desktop-only>of Action</a><li class="is-combo-treatment nav-item nav-list"><a class=nav-link href="/combination-treatment/">Combination <br>Treatment</a> <a class=subnav-expand></a><ul class=subnav><li class=nav-item><a class=nav-link href="/combination-treatment/">MOA</a><li class=nav-item><a class=nav-link href="/combination-treatment/combination-therapy/">Combination Therapy</a><li class=nav-item><a class=nav-link href="/combination-treatment/addon-therapy/">Add-on Therapy</a><li class=nav-item><a class=nav-link href="/combination-treatment/safety/">Safety</a><li class=nav-item><a class=nav-link href="/combination-treatment/dosing/">Dosing</a></ul><li class="nav-item nav-list"><a class=nav-link href="/efficacy/">Efficacy</a> <a class=subnav-expand></a><ul class=subnav><li class=nav-item><a class=nav-link href="/efficacy/">Study Design</a><li class=nav-item><a class="nav-link lesser-padding" href="/efficacy/clinical-studies/">Efficacy Results</a><li class=nav-item><a class="nav-link lesser-padding" href="/efficacy/pillar-study-design/">Adults ≥65 (PILLAR): <br class=footer-only-break>Study Design</a><li class=nav-item><a class="nav-link lesser-padding" href="/efficacy/pillar-results/">Adults ≥65 (PILLAR): <br class=footer-only-break>Efficacy Results</a></ul><li class="nav-item nav-list"><a class=nav-link href="/elderly-care/">Elderly <br class=desktop-only>Care</a><li class="nav-item nav-list"><a class=nav-link href="/safety/">Safety</a> <a class=subnav-expand></a><ul class=subnav><li class=nav-item><a class=nav-link href="/safety/">Safety Results</a><li class=nav-item><a class="nav-link lesser-padding" href="/safety/pillar-results/">Adults ≥65 (PILLAR): <br class=footer-only-break>Safety Results </a></ul><li class="nav-item nav-list access-list"><a class=nav-link href="/downloadable-resources/">Resources</a> <a class=subnav-expand></a><li class="nav-item nav-list"><a class=nav-link href="/dosing/">Dosing &amp; <br>Administration</a> <a class=subnav-expand></a><ul class=subnav><li class=nav-item><a class=nav-link href="/dosing/">Dosing</a><li class=nav-item><a class=nav-link href="/dosing/drug-interactions/">Drug-to-Drug Interactions</a></ul></ul></div></div></div><footer class=l-footer><div class="container cf"><div class="left-rhythm-padding right-rhythm-padding"><div class=footer-logo><a href="https://www.astellas.us/" target=_blank rel=noopener> <img src=/Content/img/footer-astellas-logo.png alt="Astellas Pharma Inc. logo"> </a></div><div class=footer-content><p>All trademarks are the property of their respective owners.<p>This site is intended for US Healthcare Professionals&nbsp;only. <br class=mobile-only>&copy;2024 Astellas Pharma Inc. or its affiliates.<p>055-0402-PM &nbsp;MAT-US-MYR-2024-00022&nbsp;&nbsp;&nbsp;&nbsp;6/24 MAT-US-MYR-2025-00001&nbsp;&nbsp;&nbsp;&nbsp;1/25</div></div></div><div class=container><div class="left-rhythm-padding right-rhythm-padding"><div class="footer-links cf"><ul><li><a target=_blank href=https://www.astellas.com/us/privacy-policy rel=noopener>Privacy Policy</a><li><a target=_blank href=https://www.astellas.com/us/legal rel=noopener>Legal Disclaimer</a><li><a target=_blank href=https://www.astellas.com/us/contact-us rel=noopener>Contact Us</a><li><a target=_blank href=https://www.astellas.com/us/accessibility rel=noopener>Accessibility</a><li><a class=AMIExit href=#>Medical Information</a></ul></div></div></div></footer><div class="modal fade" id=enterModal tabindex=-1 data-keyboard=false role=dialog aria-hidden=true><div class="modal-dialog interstitial"><div class=modal-content><div class="modal-body text-center"><h3 class=text-uppercase><strong>THIS WEBSITE IS INTENDED FOR <br class=desktop-only>US HEALTHCARE PROFESSIONALS ONLY.</strong></h3><p class=small>I certify that I am a healthcare professional in the US.<div class="button-group d-flex justify-content-space-around"><a href=http://www.myrbetriq.com class=m-btn-light-grey>NO</a> <a href=# class=m-btn-yellow id=hcp-confirm data-dismiss=modal>YES</a></div></div></div></div></div><div class="modal fade is-exitmodal" id=exitModal tabindex=-1 role=dialog aria-hidden=true style=display:none><div class=modal-dialog><div class=modal-content><div class=modal-header><a class=close data-dismiss=modal title="Close modal"><span aria-hidden=true>×</span></a></div><div class=modal-body><h2>You are now leaving MyrbetriqHCP.com</h2><p class="exittext twitter" style=display:block>You are now leaving myrbetriqhcp.com. The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on the&nbsp;site. <br><br>Continue to Twitter.<div class="button-group cf"><a class=modal-cancel data-dismiss=modal>Cancel</a> <a id=continueBtn-exitModal class="m-cta-btn modal-cta center continueBtn" href="https://twitter.com/intent/tweet?text=You%20might%20be%20interested%20in%20this%20website%3A%20http%3A%2F%2Fwww.myrbetriqhcp.com" target=_blank rel=noopener data-href="https://twitter.com/intent/tweet?text=You%20might%20be%20interested%20in%20this%20website%3A%20http%3A%2F%2Fwww.myrbetriqhcp.com">Continue</a></div><p>This website is funded and developed by Astellas Pharma US, Inc. Myrbetriq is a registered trademark of Astellas Pharma Inc.</div></div></div></div><div class="modal fade is-exitmodal in" id=AMIexitModal tabindex=-1 role=dialog aria-hidden=true style=display:none><div class=modal-dialog><div class=modal-content><div class=modal-header><a class=close data-dismiss=modal title="Close modal"></a></div><div class=modal-body><h2>You are now leaving MyrbetriqHCP.com</h2><p class="exittext twitter" style=display:block>By clicking &ldquo;Continue,&rdquo; you will leave MyrbetriqHCP.com and enter AstellasAnswers.com. The information contained on Astellas Medical Information is intended for U.S. healthcare professionals only.<div class="button-group cf"><a class=modal-cancel data-dismiss=modal>Cancel</a> <a id=continueBtn-AMIexitModal class="m-btn-yellow continueBtn" href=https://astellasmedinfo.com/click-to-chat.aspx target=_blank rel=noopener data-href=https://astellasmedinfo.com/click-to-chat.aspx>Continue</a></div><p class=footnote>This website is funded and developed by Astellas Pharma US, Inc. Myrbetriq is a registered trademark of Astellas Pharma Inc.</div></div></div></div><div class="modal fade is-study-modal" id=studyModal tabindex=-1 role=dialog aria-hidden=true style=display:none><div class=modal-dialog><div class="modal-content momentum-savings"><div class=modal-header><h3>Eligibility Restrictions, Terms&nbsp;&&nbsp;Conditions</h3><a class=close data-dismiss=modal><span aria-hidden=true><img src=/Content/img/icons/icon-close-x.png alt="Close modal"></span></a></div><div class=modal-body><p><strong>TO THE PATIENT:</strong> This offer is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, CHAMPUS, Puerto Rico Government Health Insurance, or any State Patient or Pharmaceutical Assistance Program. This offer is void where prohibited by law. Certain rules and restrictions apply.<p><strong>Note:</strong> If you use a mail-order pharmacy, please contact your pharmacy provider to ensure that this offer will be accepted. If the mail-order pharmacy will not process your voucher, please call <span class=disable-mobile-highlight>1&#8209;866&#8209;666&#8209;8244</span> (Monday-Friday, 8&nbsp;a.m.-8&nbsp;p.m. ET, excluding holidays) and request to speak to an agent. An agent will mail a Direct Member Reimbursement (DMR) form to you. The form should be completed and returned to the address on the form, along with your pharmacy receipt. If you are eligible, you will receive your benefit in the mail. You can also visit www.patientrebateonline.com to obtain a DMR form.<p><strong>TO THE PHARMACIST:</strong> By redeeming this coupon, I certify that (i) I have received this coupon from an eligible patient, (ii) I have dispensed the products indicated, (iii) I have not submitted, and will not submit, a claim for reimbursement to Part D of Medicare, Medicaid, or any similar federal or state program, including a state pharmaceutical assistance program, and (iv) I will otherwise comply with the terms hereof.<p>I further certify that my participation in this program is consistent with all applicable state laws and any obligations, contractual or otherwise, that I have as a pharmacy provider. Please submit the amount of co&#8209;pay authorized by the patient's primary insurance as a secondary transaction to McKesson. For pharmacy processing assistance or questions, please call the Help Desk at <span class=disable-mobile-highlight>1-866-666-8244</span>.<p><strong>HOURS OF OPERATION:</strong> Monday-Friday, 8&nbsp;a.m.-8&nbsp;p.m. ET, excluding holidays.<p>Astellas reserves the right to rescind, revoke, or amend this offer without notice. This program is not insurance.</div></div></div></div><div class="modal fade is-home" id=isHomeVideo tabindex=-1 role=dialog aria-hidden=true style=display:none><div class=modal-dialog><div class="modal-content home-video"><div class=modal-header><div class=close-home-modal data-dismiss=modal>X</div></div><div class=modal-body><script src=https://fast.wistia.com/embed/medias/0fdx95ty24.jsonp async></script><script src=https://fast.wistia.com/assets/external/E-v1.js async></script><div class=wistia_responsive_padding style="padding:67.71% 0 0 0;position:relative"><div class=wistia_responsive_wrapper style=height:100%;left:0;position:absolute;top:0;width:100%><div class="wistia_embed wistia_async_0fdx95ty24 seo=false videoFoam=true" style=height:100%;position:relative;width:100%><div class=wistia_swatch style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%"><img src=https://fast.wistia.com/embed/medias/0fdx95ty24/swatch style=filter:blur(5px);height:100%;object-fit:contain;width:100% alt="" aria-hidden=true onload="this.parentNode.style.opacity=1"></div></div></div></div></div></div></div></div><div class="modal fade is-home" id=isBarnesVideo tabindex=-1 role=dialog aria-hidden=true style=display:none><div class=modal-dialog><div class="modal-content home-video"><div class=modal-header><div class=close-home-modal data-dismiss=modal>X</div></div><div class=modal-body><script src=https://fast.wistia.com/embed/medias/vwwevn6uf4.jsonp async></script><script src=https://fast.wistia.com/assets/external/E-v1.js async></script><div class=wistia_responsive_padding style="padding:67.71% 0 0 0;position:relative"><div class=wistia_responsive_wrapper style=height:100%;left:0;position:absolute;top:0;width:100%><div class="wistia_embed wistia_async_vwwevn6uf4 seo=false videoFoam=true" style=height:100%;position:relative;width:100%><div class=wistia_swatch style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%"><img src=https://fast.wistia.com/embed/medias/vwwevn6uf4/swatch style=filter:blur(5px);height:100%;object-fit:contain;width:100% alt="" aria-hidden=true onload="this.parentNode.style.opacity=1"></div></div></div></div></div></div></div></div><script src="/bundles/foot?v=drVHEqbo-RdBxfS6qlNPyhB8WTX9y2qjXihJB5XB45c1"></script><div class="b-landscape-mode js-landscape-mode"></div><script>var getUrlParameter=function getUrlParameter(sParam){var pageURL=decodeURIComponent(window.location.search.substring(1));var pageURLVariables=pageURL.split('&');var paramName;for(var i=0;i<pageURLVariables.length;i++){paramName=pageURLVariables[i].split('=');if(paramName[0]===sParam){return paramName[1]===undefined?true:paramName[1];}}};function KatalyticsReady(){$(document).trigger("SetVariable",{name:"Visitor ID",value:"4fc746a0334947328970e0ed0d9dcf95"});var uid=getUrlParameter("uid");$(document).trigger("SetVariable",{name:"VeevaUID",value:encodeURIComponent(uid)});}
jQuery.validator.addMethod("mustbetrue",function(value,element){return element.checked;});jQuery.validator.unobtrusive.adapters.addBool("mustbetrue");</script><script src=https://vjs.zencdn.net/8.3.0/video.min.js></script><script>document.addEventListener('DOMContentLoaded',function(){function updateStyling(span,fieldClass){if(!span){console.error('No span found');return;}
var fieldParent=document.querySelector('.'+fieldClass);if(!fieldParent){console.error('No element with class "'+fieldClass+'" found');return;}
if(span.classList.contains('field-validation-error')){fieldParent.classList.add('error-icon');console.log('There be an error arrrr for '+fieldClass);}else{fieldParent.classList.remove('error-icon');console.log('No error arrrrgreat for '+fieldClass);}}
var observerConfig={childList:true,subtree:true};var observerCallback=function(mutationsList){mutationsList.forEach(function(mutation){if(mutation.type==='childList'){updateStyling(document.querySelector('span[data-valmsg-for="Address1"]'),'Addressparent');updateStyling(document.querySelector('span[data-valmsg-for="City"]'),'CityParent');updateStyling(document.querySelector('span[data-valmsg-for="Zip"]'),'ZipParent');updateStyling(document.querySelector('span[data-valmsg-for="Npi"]'),'NpiParent');}});};var observer=new MutationObserver(observerCallback);var dynamicFormParent=document.getElementById('dinamychcps');if(dynamicFormParent){observer.observe(dynamicFormParent,observerConfig);updateStyling(document.querySelector('span[data-valmsg-for="Address1"]'),'Addressparent');updateStyling(document.querySelector('span[data-valmsg-for="City"]'),'CityParent');updateStyling(document.querySelector('span[data-valmsg-for="Zip"]'),'ZipParent');updateStyling(document.querySelector('span[data-valmsg-for="Npi"]'),'NpiParent');}else{console.error('No parent div found for the dynamic form');}});</script>

Whois info of domain

Domain Name: OAB3.COM
Registry Domain ID: 2502166700_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.markmonitor.com
Registrar URL: http://www.markmonitor.com
Updated Date: 2022-08-18T21:03:26Z
Creation Date: 2020-03-10T19:36:00Z
Registry Expiry Date: 2026-03-10T19:36:00Z
Registrar: MarkMonitor Inc.
Registrar IANA ID: 292
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.2086851750
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS47.DOMAINCONTROL.COM
Name Server: NS48.DOMAINCONTROL.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2025-05-09T04:17:06Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
TERMS OF USE: You are not authorized to access or query our Whois
by the following terms of use: You agree that you may use this Data only
to: (1) allow, enable, or otherwise support the transmission of mass